头孢西丁与碳青霉烯类作为产超广谱β-内酰胺酶肺炎克雷伯菌菌血症在重症监护室的确定性治疗比较:倾向匹配回顾性分析
该回顾性研究纳入2013年1月至2023年1月在瓜德罗普大学医院ICU住院的110例单微生物产ESBL肺炎克雷伯菌菌血症患者,63例(57%)接受头孢西丁确定性治疗,47例(43%)接受碳青霉烯类治疗。30天临床成功(复合终点:30天生存、无复发、未更换抗生素)头孢西丁组57% vs 碳青霉烯组53%,p=0.823,倾向评分调整及匹配分析确认该结果。头孢西丁组更换确定性抗生素更频繁(17% vs 0%,p=0.002),碳青霉烯组碳青霉烯耐药铜绿假单胞菌获得率显著更高(23% vs 5%,p=0.007)。作者认为头孢西丁可作为部分ESBL-KP菌血症的确定性治疗选择,以节省碳青霉烯类并减少碳青霉烯耐药铜绿假单胞菌的选择。
要点
- 在ICU产ESBL肺炎克雷伯菌菌血症患者中,头孢西丁确定性治疗30天临床成功率为57%,碳青霉烯类为53%,差异无统计学意义(p=0.823)。
- 倾向评分调整及倾向评分匹配分析均确认头孢西丁与碳青霉烯类30天临床成功率无显著差异。
- 头孢西丁组更换确定性抗生素的比例显著高于碳青霉烯组(17% vs 0%,p=0.002)。
- 接受碳青霉烯类治疗的患者碳青霉烯耐药铜绿假单胞菌获得率显著高于头孢西丁组(23% vs 5%,p=0.007)。
- 作者认为头孢西丁可作为部分ESBL-KP菌血症的确定性治疗选择,以节省碳青霉烯类并减少碳青霉烯耐药铜绿假单胞菌的选择。
适用人群与场景
- 2013年1月至2023年1月在瓜德罗普大学医院ICU住院的单微生物产ESBL肺炎克雷伯菌菌血症患者,共110例。
研究设计与关键结果
- 研究类型:回顾性研究;样本量110例;单中心(瓜德罗普大学医院);人群为ICU单微生物产ESBL肺炎克雷伯菌菌血症患者。
- 干预与对照:头孢西丁确定性治疗63例(57%)vs 碳青霉烯类确定性治疗47例(43%)。
- 主要终点:30天临床成功(复合终点:30天生存、无复发、未更换抗生素)头孢西丁组57% vs 碳青霉烯组53%,p=0.823,差异无统计学意义;倾向评分调整及倾向评分匹配分析确认该结果。
- 关键次要终点:更换确定性抗生素头孢西丁组17% vs 碳青霉烯组0%,p=0.002;碳青霉烯耐药铜绿假单胞菌获得率碳青霉烯组23% vs 头孢西丁组5%,p=0.007;其他次要终点无显著差异。
证据类型、等级与局限
- 证据类型:回顾性研究;局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,头孢西丁作为确定性抗生素治疗可能是部分产ESBL肺炎克雷伯菌菌血症的治疗选择,可节省碳青霉烯类并减少碳青霉烯耐药铜绿假单胞菌菌株的选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite cefoxitin's in vitro resistance to hydrolysis by extended-spectrum beta-lactamases (ESBL), treatment of ESBL-producing Klebsiella pneumoniae (KP) infections with cefoxitin remains controversial. The aim of our study was to compare the clinical efficacy of cefoxitin as definitive antibiotic therapy for patients with ESBL-KP bacteremia in intensive care unit, versus carbapenem therapy.
METHODS: This retrospective study included all patients with monomicrobial bacteremia hospitalized in intensive care unit between January 2013 and January 2023 at the University Hospital of Guadeloupe. The primary outcome was the 30-day clinical success defined as a composite endpoint: 30-day survival, absence of relapse and no change of antibiotic therapy. Cox regression including a propensity score (PS) and PS-based matched analysis were performed for endpoint analysis.
RESULTS: A total of 110 patients with bloodstream infections were enrolled. Sixty-three patients (57%) received definitive antibiotic therapy with cefoxitin, while forty-seven (43%) were treated with carbapenems. 30-day clinical success was not significantly different between patients treated with cefoxitin (57%) and carbapenems (53%, p = 0.823). PS-adjusted and PS-matched analysis confirmed these findings. Change of definitive antibiotic therapy was more frequent in the cefoxitin group (17% vs. 0%, p = 0.002). No significant differences were observed for the other secondary endpoints. The acquisition of carbapenem-resistant Pseudomonas aeruginosa was significantly higher in patients receiving carbapenem therapy (5% vs. 23%, p = 0.007).
CONCLUSIONS: Our results suggest that cefoxitin as definitive antibiotic therapy could be a therapeutic option for some ESBL-KP bacteremia, sparing carbapenems and reducing the selection of carbapenem-resistant Pseudomonas aeruginosa strains.
参考来源
- Dequidt T, Bastian S, Nacher M, et al. Cefoxitin versus carbapenems as definitive treatment for extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteremia in intensive care unit: a propensity-matched retrospective analysis. Crit Care. 2023. PMID: 37915017. doi:10.1186/s13054-023-04712-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。